A phase II study evaluating the safety and immunogenicity of a new TB vaccine, MVA85A, in healthy children and infants after BCG vaccination at birth.
Latest Information Update: 09 Nov 2021
Price :
$35 *
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 12 Feb 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2009 Planned number of patients changed from 108 to 168 as reported by ClinicalTrials.gov.